Steven Louis Greco

US Patent:

8642543, Feb 4, 2014

Filed:

May 21, 2009

Appl. No.:

12/470427

Inventors:

Nikolaos Tezapsidis - West Orange NJ, US
Steven Greco - Carlstadt NJ, US
Mark Smith - Chagrin Falls OH, US

Assignee:

Neurotez, Inc. - Bridgewater NJ

International Classification:

A61K 38/22

US Classification:

514 58, 514 178, 514 182

Abstract:

The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.

US Patent:

20100113358, May 6, 2010

Filed:

Nov 4, 2009

Appl. No.:

12/612613

Inventors:

Nikolaos Tezapsidis - West Orange NJ, US
Steven J. Greco - Carlstadt NJ, US
Mark Smith - Cleveland OH, US

International Classification:

A61K 38/22
A61P 25/00
A61P 25/28
C12Q 1/48
G01N 33/573
G01N 33/00

US Classification:

514 12, 435 15, 435 74, 435 792

Abstract:

The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of Aβ, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles.

US Patent:

20120231457, Sep 13, 2012

Filed:

Mar 9, 2012

Appl. No.:

13/415940

Inventors:

Nikolaos Tezapsidis - West Orange NJ, US
Steven J. Greco - Carlstadt NJ, US

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

The described invention provides compositions and methods for assessing a genetic risk of developing late-onset Alzheimer's disease (LOAD) in a subject by analyzing haplotypes of human Apolipoprotein E (APOE) and Translocase of Outer Mitochondrial Membrane 40 homolog (TOMM40) genes using a PCR- and restriction digest-based approach.